Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Alternative treatment options

From: Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand

Options Adjuvant imatinib treatment Treatment after recurrence occurred
Recurrence Progression
Option 1
(baseline case)
No Imatinib BSC
Option 2.1
Option 2.2
1 year
3 years
Imatinib (recurrence occurred after adjuvant therapy completed) BSC
BSC (recurrence occurred during adjuvant therapy)  
Option 3.1
Option 3.2
1 year
3 years
Imatinib (recurrence occurred after adjuvant therapy completed) Sunitinib
Sunitinib (recurrence occurred during adjuvant therapy) BSC
Option 4 No Imatinib Sunitinib
  1. BSC best supportive care